Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
South Korea
· Delayed Price · Currency is KRW 3,875.00
+55.00 (1.44%)
At close: Apr 17, 2025, 3:30 PM KST
Bukwang Pharmaceutical Revenue
In the year 2024, Bukwang Pharmaceutical had annual revenue of 160.09B KRW with 27.13% growth. Bukwang Pharmaceutical had revenue of 46.18B in the quarter ending December 31, 2024, with 84.57% growth.
Revenue
160.09B
Revenue Growth
+27.13%
P/S Ratio
1.66
Revenue / Employee
288.97M
Employees
554
Market Cap
265.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 160.09B | 34.16B | 27.13% |
| Dec 31, 2023 | 125.93B | -64.98B | -34.04% |
| Dec 31, 2022 | 190.91B | 8.42B | 4.61% |
| Dec 31, 2021 | 182.49B | 12.83B | 7.56% |
| Dec 31, 2020 | 169.66B | 1.47B | 0.87% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 68.13B |
| PharmaResearch | 350.12B |
| LigaChem Biosciences | 125.90B |